UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/578,139	Shuji Miyagawa	2520-0132PUS1

2292
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

INTERNATIONAL APPLICATION NO.	
PCT/JP04/16776	
I.A. FILING DATE	PRIORITY DATE
11/04/2004	11/04/2003

CONFIRMATION NO. 4669
371 FORMALITIES LETTER

OC000000040311713

Date Mailed: 03/01/2010

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to comply with the sequence rules, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Applicant filed a request or letter regarding the use of the computer readable form (CRF) of a sequence listing from another application as the CRF of the sequence listing in this application in lieu of filing a CRF in this application. The request or letter, however, does not comply with the requirements of 37 CFR 1.821(e) for the reason(s) listed below. Applicant must make the appropriate correction(s), or file a CRF in this application in compliance with 37 CFR 1.821(e), within the time period for reply set forth in the notice to avoid the abandonment of the instant application.

- No CRF has been filed for the other application, or the designated CRF from the other application is not compliant with 37 CFR 1.821-1.825.

For more information and a sample letter for requesting the use of a CFR from another application, *see* MPEP 2422.05. For more information regarding electronic filing of sequence listings, see the EFS-Web Legal Framework at http://www.uspto.gov/ebc/portal/efs/legal.htm.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

BARBARA A CAMPBELL

Telephone: (703) 756-1461

RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) no errors detected.

Application Serial Number: 10/578,139
Source: IFW0
Date Processed by STIC: 03/01/2007

ENTERED

IFWO

RAW SEQUENCE LISTING DATE: 03/01/2007
PATENT APPLICATION: US/10/578,139 TIME: 14:45:41

Input Set : N:\efs\03_01_07\10578139_efs\2007022725200132PUS1ST25.txt
Output Set: N:\CRF4\03012007\J578139.raw

<110> APPLICANT: MIYAGAWA , Shuji
MATSUNAMI , Katsuyoshi
<120> TITLE OF INVENTION: HLA-E CHIMERIC MOLECULE
<130> FILE REFERENCE: 2520-0132PUS1
<140> CURRENT APPLICATION NUMBER: US 10/578,139
<141> CURRENT FILING DATE: 2006-05-03
<160> NUMBER OF SEQ ID NOS: 92
<170> SOFTWARE: PatentIn version 3.4
<210> SEQ ID NO: 1
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric sequence
SP of HLA-E
<400> SEQUENCE: 1
Met Val Asp Gly Thr Leu Leu Leu Leu Leu Ser Glu Ala Leu Ala Leu
1 5 10 15
Thr Gln Thr Trp Ala
20
<210> SEQ ID NO: 2
<211> LENGTH: 90
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric sequence .
a1 domain of HLA-E
<400> SEQUENCE: 2
Gly Ser His Ser Leu Lys Tyr Phe His Thr Ser Val Ser Arg Pro Gly
1 5 10 15
Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln
20 25 30
Phe Val Arg Phe Asp Asn Asp Ala Ala Ser Pro Arg Met Val Pro Arg
35 40 45
Ala Pro Trp Met Glu Gln Glu Gly Ser Glu Tyr Trp Asp Arg Glu Thr
50 55 60
Arg Ser Ala Arg Asp Thr Ala Gln Ile Phe Arg Val Asn Leu Arg Thr
65 70 75 80
Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala
85 90
<210> SEQ ID NO: 3
<211> LENGTH: 92

75 <212> TYPE: PRT

RAW SEQUENCE LISTING DATE: 03/01/2007
PATENT APPLICATION: US/10/578,139 TIME: 14:45:41

Input Set : N:\efs\03_01_07\10578139_efs\20070227252001 32PUS1ST25.txt
Output Set: N:\CRF4\03012007\J578139.raw

```
     76 <213> ORGANISM: Artificial Sequence
     78 <220> FEATURE:
     79 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     80       a2 domain of HLA-E
     83 <400> SEQUENCE: 3
     85 Gly Ser His Thr Leu Gln Trp Met His Gly Cys Glu Leu Gly Pro Asp
     86 1               5                  10                  15
     89 Arg Arg Phe Leu Arg Gly Tyr Glu Gln Phe Ala Tyr Asp Gly Lys Asp
     90           20                  25                  30
     93 Tyr Leu Thr Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Val Asp Thr
     94       35                  40                  45
     97 Ala Ala Gln Ile Ser Glu Gln Lys Ser Asn Asp Ala Ser Glu Ala Glu
     98   50                  55                  60
    101 His Gln Arg Ala Tyr Leu Glu Asp Thr Cys Val Glu Trp Leu His Lys
    102 65                  70                  75                  80
    105 Tyr Leu Glu Lys Gly Lys Glu Thr Leu Leu His Leu
    106                 85                  90
    109 <210> SEQ ID NO: 4
    110 <211> LENGTH: 92
    111 <212> TYPE: PRT
    112 <213> ORGANISM: Artificial Sequence
    114 <220> FEATURE:
    115 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
    116       a3 domain of HLA-E
    119 <400> SEQUENCE: 4
    121 Glu Pro Pro Lys Thr His Val Thr His His Pro Ile Ser Asp His Glu
    122 1               5                  10                  15
    125 Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr
    126           20                  25                  30
    129 Leu Thr Trp Gln Gln Asp Gly Glu Gly His Thr Gln Asp Thr Glu Leu
    130       35                  40                  45
    133 Val Glu Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala
    134   50                  55                  60
    137 Val Val Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln
    138 65                  70                  75                  80
    141 His Glu Gly Leu Pro Glu Pro Val Thr Leu Arg Trp
    142                 85                  90
    145 <210> SEQ ID NO: 5
    146 <211> LENGTH: 63
    147 <212> TYPE: PRT
    148 <213> ORGANISM: Artificial Sequence
    150 <220> FEATURE:
    151 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
    152       Transmembrane domain of HLA-E
    155 <400> SEQUENCE: 5
    157 Lys Pro Ala Ser Gln Pro Thr Ile Pro Ile Val Gly Ile Ile Ala Gly
    158 1               5                  10                  15
    161 Leu Val Leu Leu Gly Ser Val Val Ser Gly Ala Val Val Ala Ala Val
    162           20                  25                  30
```

RAW SEQUENCE LISTING DATE: 03/01/2007
PATENT APPLICATION: US/10/578,139 TIME: 14:45:41

Input Set : N:\efs\03_01_07\10578139_efs\2007022725200132PUS1ST25.txt
Output Set: N:\CRF4\03012007\J578139.raw

```
     165 Ile Trp Arg Lys Lys Ser Ser Gly Gly Lys Gly Gly Ser Tyr Ser Lys
     166         35                  40                  45
     169 Ala Glu Trp Ser Asp Ser Ala Gln Gly Ser Glu Ser His Ser Leu
     170     50                  55                  60
     173 <210> SEQ ID NO: 6
     174 <211> LENGTH: 63
     175 <212> TYPE: DNA
     176 <213> ORGANISM: Artificial Sequence
     178 <220> FEATURE:
     179 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     180       SP of HLA-E
     183 <400> SEQUENCE: 6
     184 atggtagatg gaaccctcct tttactcctc tcggaggccc tggcccttac ccagacctgg     60
     186 gcg                                                                 63
     189 <210> SEQ ID NO: 7
     190 <211> LENGTH: 270
     191 <212> TYPE: DNA
     192 <213> ORGANISM: Artificial Sequence
     194 <220> FEATURE:
     195 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     196       a1 domain of HLA-E
     199 <400> SEQUENCE: 7
     200 ggctcccact ccttgaagta tttccacact tccgtgtccc ggcccggccg cggggagccc     60
     202 cgcttcatct ctgtgggcta cgtggacgac acccagttcg tgcgcttcga caacgacgcc    120
     204 gcgagtccga ggatggtgcc gcgggcgccg tggatggagc aggaggggtc agagtattgg    180
     206 gaccgggaga cacggagcgc cagggacacc gcacagattt tccgagtgaa tctgcggacg    240
     208 ctgcgcggct actacaatca gagcgaggcc                                    270
     211 <210> SEQ ID NO: 8
     212 <211> LENGTH: 276
     213 <212> TYPE: DNA
     214 <213> ORGANISM: Artificial Sequence
     216 <220> FEATURE:
     217 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     218       a2 domain of HLA-E
     221 <400> SEQUENCE: 8
     222 gggtctcaca ccctgcagtg gatgcatggc tgcgagctgg ggcccgacag gcgcttcctc     60
     224 cgcgggtatg aacagttcgc ctacgacggc aaggattatc tcaccctgaa tgaggacctg    120
     226 cgctcctgga ccgcggtgga cacggcggct cagatctccg agcaaaagtc aaatgatgcc    180
     228 tctgaggcgg agcaccagag agcctacctg gaagacacat gcgtggagtg gctccacaaa    240
     230 tacctggaga aggggaagga gacgctgctt cacctg                             276
     233 <210> SEQ ID NO: 9
     234 <211> LENGTH: 276
     235 <212> TYPE: DNA
     236 <213> ORGANISM: Artificial Sequence
     238 <220> FEATURE:
     239 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     240       a3 domain of HLA-E
     243 <400> SEQUENCE: 9
     244 gagcccccaa agacacacgt gactcaccac cccatctctg accatgaggc caccctgagg     60
```

RAW SEQUENCE LISTING DATE: 03/01/2007
PATENT APPLICATION: US/10/578,139 TIME: 14:45:41

Input Set : N:\efs\03_01_07\10578139_efs\2007022725200132PUS1ST25.txt
Output Set: N:\CRF4\03012007\J578139.raw

```
246 tgctgggccc tgggcttcta ccctgcggag atcacactga cctggcagca ggatggggag    120
248 ggccataccc aggacacgga gctcgtggag accaggcctg caggggatgg aaccttccag    180
250 aagtgggcag ctgtggtggt gccttctgga gaggagcaga gatacacgtg ccatgtgcag    240
252 catgaggggc tacccgagcc cgtcaccctg agatgg                             276
255 <210> SEQ ID NO: 10
256 <211> LENGTH: 192
257 <212> TYPE: DNA
258 <213> ORGANISM: Artificial Sequence
260 <220> FEATURE:
261 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
262       Transmembrane domain of HLA-E
265 <400> SEQUENCE: 10
266 aagccggctt cccagcccac catccccatc gtgggcatca ttgctggcct ggttctcctt     60
268 ggatctgtgg tctctggagc tgtggttgct gctgtgatat ggaggaagaa gagctcaggt    120
270 ggaaaaggag ggagctactc taaggctgag tggagcgaca gtgcccaggg gtctgagtct    180
272 cacagcttgt aa                                                       192
275 <210> SEQ ID NO: 11
276 <211> LENGTH: 24
277 <212> TYPE: PRT
278 <213> ORGANISM: Artificial Sequence
280 <220> FEATURE:
281 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
282       SP of HLA-G1
285 <400> SEQUENCE: 11
287 Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala
288 1               5                   10                  15
291 Leu Thr Leu Thr Glu Thr Trp Ala
292             20
295 <210> SEQ ID NO: 12
296 <211> LENGTH: 90
297 <212> TYPE: PRT
298 <213> ORGANISM: Artificial Sequence
300 <220> FEATURE:
301 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
302       a1 domain of HLA-G1
305 <400> SEQUENCE: 12
307 Gly Ser His Ser Met Arg Tyr Phe Ser Ala Ala Val Ser Arg Pro Gly
308 1               5                   10                  15
311 Arg Gly Glu Pro Arg Phe Ile Ala Met Gly Tyr Val Asp Asp Thr Gln
312             20                  25                  30
315 Phe Val Arg Phe Asp Ser Asp Ser Ala Cys Pro Arg Met Glu Pro Arg
316         35                  40                  45
319 Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Glu Glu Glu Thr
320     50                  55                  60
323 Arg Asn Thr Lys Ala His Ala Gln Thr Asp Arg Met Asn Leu Gln Thr
324 65                  70                  75                  80
327 Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala
328                 85                  90
331 <210> SEQ ID NO: 13
```

RAW SEQUENCE LISTING DATE: 03/01/2007
PATENT APPLICATION: US/10/578,139 TIME: 14:45:41

Input Set : N:\efs\03_01_07\10578139_efs\20070227252001 32PUS1ST25.txt
Output Set: N:\CRF4\03012007\J578139.raw

```
     332 <211> LENGTH: 92
     333 <212> TYPE: PRT
     334 <213> ORGANISM: Artificial Sequence
     336 <220> FEATURE:
     337 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     338       a2 domain of HLA-G1
     341 <400> SEQUENCE: 13
     343 Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly Ser Asp
     344 1               5                   10                  15
     347 Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly Lys Asp
     348             20                  25                  30
     351 Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr
     352         35                  40                  45
     355 Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val Ala Glu
     356     50                  55                  60
     359 Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu His Arg
     360 65                  70                  75                  80
     363 Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala
     364                 85                  90
     367 <210> SEQ ID NO: 14
     368 <211> LENGTH: 92
     369 <212> TYPE: PRT
     370 <213> ORGANISM: Artificial Sequence
     372 <220> FEATURE:
     373 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     374       a3 domain of HLA-G1
     377 <400> SEQUENCE: 14
     379 Asp Pro Pro Lys Thr His Val Thr His His Pro Val Phe Asp Tyr Glu
     380 1               5                   10                  15
     383 Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile
     384             20                  25                  30
     387 Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu
     388         35                  40                  45
     391 Val Glu Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala
     392     50                  55                  60
     395 Val Val Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln
     396 65                  70                  75                  80
     399 His Glu Gly Leu Pro Glu Pro Leu Met Leu Arg Trp
     400                 85                  90
     403 <210> SEQ ID NO: 15
     404 <211> LENGTH: 40
     405 <212> TYPE: PRT
     406 <213> ORGANISM: Artificial Sequence
     408 <220> FEATURE:
     409 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic chimeric
sequence
     410       Transmembrane domain of HLA-G1
     413 <400> SEQUENCE: 15
     415 Lys Gln Ser Ser Leu Pro Thr Ile Pro Ile Met Gly Ile Val Ala Gly
     416 1               5                   10                  15
```

VERIFICATION SUMMARY DATE: 03/01/2007
PATENT APPLICATION: **US/10/578,139** TIME: 14:45:42

Input Set : **N:\efs\03_01_07\10578139_efs\2007022725200132PUS1ST25.txt**
Output Set: **N:\CRF4\03012007\J578139.raw**

BOX SEQUENCE
PATENT
2520-0132PUS1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
MIYAGAWA , Shuji et al.

Application No.: 10/578,139 Confirmation No.: 4669

Filed: May 3, 2006 Art Unit: Not Yet Assigned

For: HLA-E CHIMERIC MOLECULE Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

Sir:

Applicants have received a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 1, 2010.

Applicants first note that a Sequence Listing for the present application has been received as evidenced by its appearance on PAIR (see attached printout). A Computer Readable Form (CRF) copy and amendment were submitted concurrent with the Sequence Listing found on PAIR.

Despite already submitting the CRF copy and only to expedite processing, Applicants enclose herewith a Substitute Sequence Listing in full compliance with 37 C.F.R. §§1.821-1.825. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is an electronic CRF copy of the Substitute Sequence Listing. The electronic CRF copy of the Substitute Sequence Listing, file "2007-02-27 2520-

0132PUS1_ST25.txt", is identical to the paper copy, except that it lacks formatting. The enclosed paper copy and the electronic CRF copy of the Substitute Sequence Listing do not include new matter.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

APR 30 2010

By _____ #32868
for Gerald M. Murphy, Jr., #28,977

BIRCH, STEWART, KOLASCH & BIRCH, LLP
P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/psq
2520-0132PUS1

Attachments:
Electronic CRF Copy of Substitute Sequence Listing
Paper Copy of Substitute Sequence Listing
Copy of Notice to Comply
Copy of PAIR printout